Apadenoson

DB05009InvestigationalSmall molecule

Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies. It is developed by Bristol-Myers Squibb and is in...

Mechanism: BMS068645 is designed to selectively stimulate the A2a adenosine receptor responsible for coronary vasodilation. Research to date suggests that this compound could potentially reduce or eliminate side effects associated with currently available pharmacologic stress agents that are not selective for the A2a adenosine receptor.
Curator reviewed
Primary indication: Investigated for use/treatment in cardiovascular disorders and inflammatory disorders (unspecified).Curator reviewed
Formula / weight: C₂₃H₃₀N₆O₆ · 486.529 g/mol (avg)
Code names: BMS-068645 · DWH-146E

Resolves to

Compound

UNIIBTS1Y6777MCAS250386-15-3ChEMBLCHEMBL1950649PubChem9805430

Structure

InChIKeyFLEVIENZILQUKB-XTWQNQIISA-NSMILESCCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=C(N=C2N)C#CC[C@H]1CC[C@@H](CC1)C(=O)OC

Targets

P29274ADORA2A

What you can answer from here — as of August 26, 2024

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Apadenoson, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account